1-Jahres-Chart
5-Tage-Chart
| Realtime | Geld | Brief | Zeit |
|---|---|---|---|
| 3,440 | 3,580 | 04.06. |
- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 25.04. | Zydus Lifesciences Limited Signs Purchase Agreement with PAI Partners and Other Shareholders to Acquire a Majority Stake in Amplitude Surgical SA | 335 | Business Wire | Regulatory News:
Amplitude Surgical SA (Paris:AMPLI):
Following the joint announcement of March 11, 2025, Zydus Lifesciences Limited ("Zydus") and Amplitude Surgical SA (Paris:AMPLI) ("Amplitude")... ► Artikel lesen | |
| 17.04. | Amplitude Surgical - 9-Months Consolidated Sales for FY 2024-25 of €83.8m, up +6.4% at Constant Exchange Rates | 244 | Business Wire | Sales up +6.6% at constant exchange rates in Q3 FY 2024-25
Consolidated sales for 9 months up+ 6.4% at constant exchange rates to €83.8m
Good momentum in France: sales up +4.7% over... ► Artikel lesen | |
| 17.04. | Zydus Lifesciences Limited announces the execution of undertakings to tender as part of its envisaged tender offer for Amplitude Surgical SA shares | 241 | PR Newswire | AHMEDABAD, India and PARIS, April 17, 2025 /PRNewswire/ -- Following the announcement of its envisaged tender offer on March 11, 2025, Zydus Lifesciences Limited announces the execution of... ► Artikel lesen | |
| 17.04. | Amplitude Surgical Has Been Informed by Zydus Lifesciences Limited of the Execution of Undertakings to Tender as Part of Its Envisaged Tender Offer for Amplitude Surgical SA Shares | 202 | Business Wire | Regulatory News:
Amplitude Surgical (ISIN: FR0012789667, Mnemo: AMPLI, PEA-PME eligible).
Following the announcement of the envisaged tender offer on March 11, 2025 of Zydus Lifesciences Limited... ► Artikel lesen | |
| 26.03. | Amplitude Surgical Announces H1 2024-25 Results: 51.5 M€ Sales and 13.1 M€ EBITDA | 316 | Business Wire | Consolidated sales of €51.5m, up 6.3% at constant exchange rates
EBITDA up 10.6% to €13.1 million, EBITDA margin 25.4%
Current operating income of €6.0 million
Cash position... ► Artikel lesen | |
| 12.03. | XFRA 1AU: WIEDERAUFNAHME/RESUMPTION | 177 | Xetra Newsboard | FOLGENDE(S) INSTRUMENT(E) WIRD/ WERDEN WIEDER IN DEN HANDEL AUFGENOMMEN MIT FOLGENDEM TRADING SCHEDULE.THE FOLLOWING INSTRUMENT(S) IS/ARE RESUMED TRADING WITH FOLLOWING TRADING SCHEDULE:INSTRUMENT NAME... ► Artikel lesen | |
| 11.03. | XFRA 1AU: AUSSETZUNG/SUSPENSION | 203 | Xetra Newsboard | DAS/ DIE FOLGENDE(N) INSTRUMENT(E) IST/ SIND AB SOFORT AUSGESETZT:THE FOLLOWING INSTRUMENT(S) IS/ ARE SUSPENDED WITH IMMEDIATE EFFECT:INSTRUMENT NAME KUERZEL/SHORTCODE ISIN BIS/UNTILAMPLITUDE SURGIC.... ► Artikel lesen | |
| 11.03. | Zydus Life inks pact to acquire majority stake in Amplitude Surgical | 2 | capitalmarket.com | ||
| AMPLITUDE SURGICAL Aktie jetzt für 0€ handeln | |||||
| 11.03. | Zydus Enters Exclusive Negotiations with PAI Partners and Other Shareholders to Acquire a Majority stake in Amplitude Surgical, France | 321 | Business Wire | Completion of the transaction to be followed by mandatory simplified tender offer
Zydus has entered into exclusive negotiations to acquire a controlling shareholding in Amplitude Surgical,... ► Artikel lesen | |
| 20.02. | Amplitude Surgical - 1st Half-year 2024-25: Consolidated Sales of €51.5m, +6.3% at Constant Exchange Rates | 291 | Business Wire | Consolidated sales of €51.5 million, up+ 6.3% at constant exchange rates
Good sales growth in France at +4.6%
Strong growth in international business thanks to subsidiaries, with... ► Artikel lesen | |
| 21.11.24 | Amplitude Surgical - First Quarter 2024-25: Consolidated Sales of €21.8m, +7.5% at Constant Exchange Rates | 567 | Business Wire | VALENCE, France--(BUSINESS WIRE)--Regulatory News:
Amplitude Surgical (ISIN: FR0012789667, Mnemo: AMPLI, PEA-PME eligible), the French market leader in surgical technologies for lower limb orthopedics... ► Artikel lesen | |
| 20.11.24 | Amplitude Surgical Announces Its 2024-25 Financial Calendar | 112 | Business Wire | Regulatory News:
Amplitude Surgical (ISIN: FR0012789667, Mnemo: AMPLI, PEA-PME eligible), the French market leader in surgical technologies for lower limb orthopedics, announces its financial agenda... ► Artikel lesen | |
| 23.10.24 | Amplitude Surgical - Fiscal Year 2023-24: 106.0 M€ Sales and €27.1m EBITDA | 475 | Business Wire | Consolidated sales of €106.0 million, up 6.3% at constant exchange rates
EBITDA up to €27.1m (+3.7%), EBITDA rate at 25.6%.
Current operating income of €12.7 million
Cash... ► Artikel lesen | |
| 25.07.24 | Amplitude Surgical - Consolidated Annual Sales of €106.0m, up +6.3% at Constant Exchange Rates | 273 | Business Wire | Growth of 7.0% at constant exchange rates in the fourth quarter of FY 2023-2024 and 6.3% for the full year
5.0% sales growth in France
Good momentum outside France, with sales up... ► Artikel lesen |
14 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| BICO GROUP | 3,346 | -0,18 % | Schock-News für Bico Group Anleger vor dem Wochenende: So müssen Sie heute noch auf diese Sondermeldung reagieren! | ||
| PING AN HEALTHCARE | 0,779 | -2,19 % | PA GOODDOCTOR (01833): FORM OF PROXY FOR USE AT ANNUAL GENERAL MEETING | ||
| ORGANON | 8,392 | +0,65 % | Organon & Co.: Die US-amerikanische Arzneimittelbehörde FDA erteilt Samsung Bioepis und Organon die Zulassung für die Austauschbarkeit von HADLIMA (Adalimumab-bwwd) Injektion | HADLIMA (Adalimumab-bwwd) Injektion, 40 mg/0,4 ml und 40 mg/0,8 ml, ist nun austauschbar mit allen hoch- und niedrigkonzentrierten Darreichungsformen (Autoinjektor, Fertigspritze und Einzeldosis-Durchstechflasche)... ► Artikel lesen | |
| EMEIS | 10,030 | -0,10 % | emeis S.A.: emeis: Documents and Information Related to the Combined General Meeting of 26 June 2025 | Regulatory News:
The Combined General Meeting (Ordinary and Extraordinary) of Shareholders of emeis S.A. (Paris:EMEIS) (the Company ») will be held on Thursday 26 June 2025 at 9:30 a.m. (Paris... ► Artikel lesen | |
| CYTOSORBENTS | 0,899 | +1,58 % | Cytosorbents Corp: CytoSorbents Reports First Quarter 2025 Financial Results and Provides Business Update | PRINCETON, N.J., May 14, 2025 /PRNewswire/ -- CytoSorbents Corporation (NASDAQ: CTSO), a leader in the treatment of life-threatening conditions in the intensive... ► Artikel lesen | |
| CLARIANE | 3,900 | -1,61 % | Clariane: Renewal of the drawdown under the Revolving Credit Facility for a six-month period | 4 June 2025
Renewal of the drawdown under the Revolving Credit Facility for a six-month periodParis, 4 June 2025 - Clariane (CLARI.PA - ISIN FR0010386334) announces that it has renewed the drawdown... ► Artikel lesen | |
| ARJO | 2,852 | +0,21 % | Dividendenbekanntmachungen (30.04.2025) | Unternehmen ISIN-Code Dividende (Währung) Dividende (EUR) AG MORTGAGE INVESTMENT TRUST INC US0012285013 0,2 USD EUR ALLIED PROPERTIES REAL ESTATE INVESTMENT ... CA0194561027 0,15 CAD 0... ► Artikel lesen | |
| M3 INC | 13,400 | +0,75 % | M3-Aktie im Höhenflug: Papier legt um 5,69 Prozent zu (13,00 €) | An der Börse brilliert derzeit die M3-Aktie . Der Kurs des Anteilsscheins legt kräftig zu. Eine Steigerung um 5,69 Prozent - mit diesem Kursplus gehört die M3-Aktie gegenwärtig zu den Papieren mit der... ► Artikel lesen | |
| DYNAVOX GROUP | 10,000 | +0,05 % | TOBII AB: Tobii extends contract with Dynavox Group and agrees on volume deal of eye tracking components | Tobii AB and Dynavox Group AB today announced the strengthening of their partnership with an extension of the existing supply contract, along with a significant volume deal for eye tracking components... ► Artikel lesen | |
| INTERPACE BIOSCIENCES | 0,655 | 0,00 % | Interpace Biosciences, Inc.: Effective May 2, 2025, Interpace Diagnostics Will No Longer Accept Specimens for PancraGEN, a Molecular Diagnostic Test That Assesses Pancreatic Cyst Cancer Risk | Interpace Expects to Remain Profitable as a Thyroid-focused Business PARSIPPANY, NJ, April 24, 2025 (GLOBE NEWSWIRE) -- Interpace Diagnostics®, a subsidiary of Interpace Biosciences®, ("Interpace"... ► Artikel lesen | |
| NYXOAH | 6,860 | +1,03 % | Nyxoah: Publication relating to transparency notifications | ||
| VIVANI MEDICAL | 0,975 | -0,51 % | Vivani Medical, Inc.: Vivani Medical Announces Filing of Form 10 Registration Statement for Planned Spin-Off of Cortigent Neurostimulation Business to Vivani Shareholders | Transaction is anticipated to be completed in third quarter 2025 Planned Cortigent Nasdaq listing intended to drive value for Vivani and Cortigent stockholders Cortigent is developing the Orion® Visual... ► Artikel lesen | |
| CHINA MEDICAL SYSTEM | 1,160 | +3,57 % | Dividendenbekanntmachungen (28.04.2025) | Unternehmen ISIN-Code Dividende (Währung) Dividende (EUR) AEON THANA SINSAP THAILAND PCL NVDR TH0664010R11 2,95 THB 0,0774 EUR BANCO DI DESIO E DELLA BRIANZA SPA IT0001041000 - 0,4566 EUR BRADESPAR... ► Artikel lesen | |
| NANOSONICS | 2,500 | 0,00 % | NANOSONICS LIMITED: Response to ASX Price Query | ||
| NIAGEN BIOSCIENCE | 10,600 | +4,95 % | ChromaDex Corp. Announces Name Change to Niagen Bioscience, Inc. and New Ticker Symbol "NAGE" Effective March 19, 2025 | LOS ANGELES--(BUSINESS WIRE)--ChromaDex Corp. (NASDAQ:CDXC), the global authority on NAD+ (nicotinamide adenine dinucleotide) with a focus on the science of healthy aging, today announced that it will... ► Artikel lesen |
Das Unternehmen AMPLITUDE SURGICAL kann der Branche Gesundheitswesen zugeordnet werden. Die relative Kursveränderung beträgt aktuell 0,00 % bei einem Aktienkurs von 6,050 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu AMPLITUDE SURGICAL finden Sie auf Wallstreet Online.